Marrow-ablative chemotherapy and autologous stem cell transplantation followed by interferon-alpha maintenance treatment versus interferon-alpha maintenance treatment alone for stage III and IV follicular Non-Hodgkin's lymphoma

European Organisation for Research and Treatment of Cancer (EORTC) (Belgium)0 个研究点目标入组 469 人开始时间: 2002年8月19日最近更新: 2019年5月5日

适应症

试验速览

•Current information as of 07/08/09:
•1. Previously untreated follicular non-Hodgkin's lymphoma presenting with stages III or IV, including nodal, Waldeyers ring and extranodal locations - at least one measurable mass should be present
•2. Above 18 years and below 66 years
•3. World Health Organisation (WHO) performance status zero to two
•4. Alkaline phosphatase and bilirubin less than 2.5 times upper limit of normal (ULN) (unless clearly related to NHL)
•5. Creatinine and BUN less than 2.5 times ULN (unless clearly related to NHL)
•Initial information at registration:
•1. Previously untreated follicular non-Hodgkin's lymphoma presenting with stages III or IV, including nodal, Waldeyers ring and extranodal locations - at least one measurable mass should be present
•2. Above 18 years and below 66 years
•3. World Health Organisation (WHO) performance status zero to two

•Current information as of 07/08/09:
•1. Prior malignancies except non-melanoma skin tumours or stage 0 in situ cervical carcinoma
•2. Severe cardiac disease (e.g. severe heart failure requiring treatment or cardiac ejection fraction less than 45%)
•3. Neurologic disease
•4. Pulmonary disease
•5. Psychiatric or metabolic disease
•6. HIV positive
•7. Pregnancy
•8. Other medical contraindications to protocol treatments
•Initial information at registration
•1. Prior malignancies except non-melanoma skin tumours or stage 0 in situ cervical carcinoma
•2. Other medical contraindications to protocol treatments

发起方

European Organisation for Research and Treatment of Cancer (EORTC) (Belgium)